Akamis is focused on leveraging its T-SIGn® platform to develop solid tumor-targeted therapeutics that enable the patient's immune system to recognize and attack cancer. They have two clinical-stage programs, NG-350A and NG-641, being investigated in Phase 1 clinical studies. Akamis also has collaborations with leaders in the immuno-oncology field, including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI).